| Dr Marjory Langer, MD | |
|
1 Bay Ave, Evergreen Emergency Solutions, Montclair, NJ 07042-4837 | |
| (973) 429-6000 | |
| Not Available |
| Full Name | Dr Marjory Langer |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 1 Bay Ave, Montclair, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750378451 | NPI | - | NPPES |
| 083666 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 25MA07848900 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph's Hospital And Medical Center | Paterson, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Advanced Urgent Care | 4385986330 | 28 |
| Passaic River Physicians Llc | 4486041514 | 52 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | St Josephs Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497791297 PECOS PAC ID: 9739171984 Enrollment ID: O20040330001612 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | St. Joseph's Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568791192 PECOS PAC ID: 5092996181 Enrollment ID: O20110223000002 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | Atlantic Urgent Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023358959 PECOS PAC ID: 2264679661 Enrollment ID: O20130502000023 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | Atlantic Advanced Urgent Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104309277 PECOS PAC ID: 4385986330 Enrollment ID: O20190424000040 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | St Josephs Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205425519 PECOS PAC ID: 8628470325 Enrollment ID: O20210716000520 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | Passaic River Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962162644 PECOS PAC ID: 4486041514 Enrollment ID: O20220420000861 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Entity Name | Passaic River Observation, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568113348 PECOS PAC ID: 0143617126 Enrollment ID: O20220421000141 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marjory Langer, MD 7 Gladding Rd, Caldwell, NJ 07006-5804 Ph: (973) 429-6200 | Dr Marjory Langer, MD 1 Bay Ave, Evergreen Emergency Solutions, Montclair, NJ 07042-4837 Ph: (973) 429-6000 |
News Archive
A system in the brain already known to regulate food intake also serves as a direct "remote control" for the way fat is stored and metabolized in the body, say University of Cincinnati (UC) researchers.
A group of Democratic senators have written a letter to Republican governors in states such as South Dakota, Wyoming, Wisconsin and Nebraska urging that they set politics aside and pursue the health law's expansion of the state-federal low-income insurance program. Meanwhile, the issue is also front and center in primary elections.
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan.
As a part of a research collaboration, scientists at the Sahlgrenska Academy at Gotenborg University, Sweden, have developed a new drug candidate against HIV-infection. The new substance, named alphaHGA, will be tested on patients this year.
BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
› Verified 8 days ago
Erik Sherman, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6000 | |
Dr. Augustine Yao Alifo, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6000 | |
Dr. Eric Fernandez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6000 | |
Dr. Larry Carter, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6000 | |
Dr. Radha Kotamraju, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6991 | |
Dr. Mitchell Jerold Heller, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6000 | |
Viktor Livshits, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Bay Ave, Montclair, NJ 07042 Phone: 973-429-6000 |